Patents by Inventor Eric G. Marcusson

Eric G. Marcusson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of KIAA1531 protein expression
    Publication number: 20040023378
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of KIAA1531 protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KIAA1531 protein. Methods of using these compounds for modulation of KIAA1531 protein expression and for treatment of diseases associated with expression of KIAA1531 protein are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Ming-Yi Chiang, Eric G. Marcusson, Kenneth W. Dobie
  • Extracellular-signal-regulated kinase-6 inhibitors for inhibiting angiogenesis
    Publication number: 20030232778
    Abstract: Compounds, compositions and methods are provided for modulating the expression of extracellular-signal-regulated kinase-6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding extracellular-signal-regulated kinase-6. Methods of using these compounds for modulation of extracellular-signal-regulated kinase-6 expression and for diagnosis and treatment of disease associated with expression extracellular-signal-regulated kinase-6 are provided.
    Type: Application
    Filed: January 17, 2003
    Publication date: December 18, 2003
    Inventors: Eric G. Marcusson, C. Frank Bennett, Kenneth W. Dobie
  • Phosphatidylinositol-4-phosphate 5-kinase, type II beta inhibitors for inhibiting angiogenesis
    Publication number: 20030232777
    Abstract: Compounds, compositions and methods are provided for modulating the expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, type II beta. Methods of using these compounds for modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression and for diagnosis and treatment of disease associated with expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta are provided.
    Type: Application
    Filed: January 16, 2003
    Publication date: December 18, 2003
    Inventors: Eric G. Marcusson, Kenneth W. Dobie, Susan M. Freier
  • Antisense modulation of Fas mediated signaling
    Patent number: 6653133
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: November 25, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Eric G. Marcusson, Jacqueline Wyatt
  • Antisense modulation of Fas mediated signaling
    Publication number: 20020004490
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Application
    Filed: March 9, 2001
    Publication date: January 10, 2002
    Inventors: Nicholas M. Dean, Eric G. Marcusson, Jacqueline Wyatt, Hong Zhang
  • Antisense inhibition of Fas mediated signaling
    Patent number: 6204055
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: March 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Eric G. Marcusson
  • Antisense modulation of novel anti-apoptotic bcl-2-related proteins
    Patent number: 6001992
    Abstract: Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: December 14, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Elizabeth J. Ackermann, C. Frank Bennett, Nicholas M. Dean, Eric G. Marcusson